Maintaining Investments in New Innovation Act
Latest action · Feb 27, 2025 Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedFeb 27, 2025
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Maintaining Investments in New Innovation Act
This bill requires drug products with genetically targeted technology to have had market approval for at least 11 years in order to qualify for the Medicare Drug Price Negotiation Program. (The program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.)
Cosponsors 51
Members who signed on, in the order they did. Signatures ran from Feb 27, 2025 to Sep 24, 2026; 13 are original cosponsors, there from the day it was introduced.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| R-FL | Aaron Bean | Original | Feb 27, 2025 |
| R-TX | Beth Van Duyne | Original | Feb 27, 2025 |
| R-UT | Blake D. Moore | Original | Feb 27, 2025 |
| R-NY | Claudia Tenney | Original | Feb 27, 2025 |
| R-TX | Dan Crenshaw | Original | Feb 27, 2025 |
| R-PA | John Joyce | Original | Feb 27, 2025 |
| D-NY | Joseph D. Morelle | Original | Feb 27, 2025 |
| D-NJ | Josh Gottheimer | Original | Feb 27, 2025 |
| R-IA | Mariannette Miller-Meeks | Original | Feb 27, 2025 |
| R-NC | Richard Hudson | Original | Feb 27, 2025 |
| R-GA | Rick W. Allen | Original | Feb 27, 2025 |
| R-IN | Rudy Yakym III | Original | Feb 27, 2025 |
| D-CA | Scott H. Peters | Original | Feb 27, 2025 |
| R-FL | Neal P. Dunn | Mar 27, 2025 | |
| R-OK | Kevin Hern | Apr 9, 2025 | |
| R-OH | Mike Carey | Apr 10, 2025 | |
| R-IN | Jefferson Shreve | May 9, 2025 | |
| R-TX | August Pfluger | May 13, 2025 | |
| R-TX | Pete Sessions | Jun 4, 2025 | |
| R-NC | Addison P. McDowell | Jun 10, 2025 | |
| R-PA | Mike Kelly | Sep 2, 2025 | |
| R-TN | Charles J. "Chuck" Fleischmann | Sep 17, 2025 | |
| D-CO | Brittany Pettersen | Sep 30, 2025 | |
| R-PA | Daniel Meuser | Sep 30, 2025 | |
| R-NY | Nicole Malliotakis | Sep 30, 2025 | |
| R-OH | Troy Balderson | Oct 3, 2025 | |
| R-NC | Tim Moore | Oct 17, 2025 | |
| R-NC | Chuck Edwards | Oct 31, 2025 | |
| R-MI | John R. Moolenaar | Oct 31, 2025 | |
| R-CA | Ken Calvert | Oct 31, 2025 | |
| R-TX | Randy K. Weber, Sr. | Oct 31, 2025 | |
| R-CA | Vince Fong | Nov 4, 2025 | |
| R-GA | Brian Jack | Nov 10, 2025 | |
| R-TX | Nathaniel Moran | Nov 17, 2025 | |
| R-FL | Laurel M. Lee | Nov 21, 2025 | |
| R-FL | Mike Haridopolos | Nov 21, 2025 | |
| R-NJ | Thomas H. Kean, Jr. | Nov 21, 2025 | |
| R-IA | Ashley Hinson | Dec 4, 2025 | |
| D-CA | Kevin Mullin | Dec 9, 2025 | |
| R-NY | Michael Lawler | Jan 13, 2026 | |
| R-KY | Andy Barr | Mar 20, 2026 | |
| R-FL | Gus M. Bilirakis | Apr 15, 2026 | |
| R-NE | Adrian Smith | Jun 18, 2026 | |
| R-PA | Lloyd Smucker | Jun 18, 2026 | |
| R-NY | Nicholas A. Langworthy | Jun 18, 2026 | |
| R-CO | Gabe Evans | Jun 25, 2026 | |
| R-GA | Earl L. "Buddy" Carter | Aug 10, 2026 | |
| D-FL | Jared Moskowitz | Aug 10, 2026 | |
| R-PA | Brian K. Fitzpatrick | Aug 27, 2026 | |
| D-TX | Vicente Gonzalez | Sep 4, 2026 | |
| R-OH | Michael A. Rulli | Sep 24, 2026 |
Committees 2
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Energy and Commerce Committee | Referred Feb 27, 2025 |
| House | Ways and Means Committee | Referred Feb 27, 2025 |
Actions 2
Everything that happened, newest first.
- Feb 27, 2025Introduced in House
- Feb 27, 2025Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Constitutional authority
The sponsor’s statement, as printed in the Congressional Record, vol. 171, no. 39, February 27, 2025, page H919.
Printed hearings 1
Hearings whose printed record names this bill, newest first: hearings on it, and wider hearings where it came up.
| Number | Hearing | Committee | Held |
|---|---|---|---|
| Serial No. 119-46 | MEMBER DAY248 pages | Energy and Commerce Committee | Dec 12, 2025 |
Titles 2
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To amend title XI of the Social Security Act to protect access to genetically targeted technologies.
- Short Title(s) as Introduced
- Maintaining Investments in New Innovation Act
Subjects
Assigned by the Library of Congress. Policy area: Health.
Text 1
Each version as it was printed, newest first.
- Feb 27, 2025Introduced in House
Support LegiList
This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.